New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
Source : https://www.mdpi.com/2075-1729/11/11/1131
Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Tumor cells may take advantage of different intracellular and genetic systems attenuating the drug effects....
Conclusion/Relevance: Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance, as they might give rise to secondary tumors when the therapy is concluded. Thus, MRDs are crucial therapeutic targets in order to prevent tumor relapse. Therefore, several groups aim at understanding how MRDs are orginated,...
-
Alireza Mirmiran4yrInteresting piece. Thanks for your insights.
-
MRD Connect4yrKey Points • Source: Life • Conclusion/Relevance: “In this review, we will describe MRD from a genetic, evolutionary, and molecular point of view. Moreover, we will focus on the new in vitro, in vivo, Show More
Minimal residual disease in multiple myeloma: an important tool in clinical trials
Source : https://www.eurekaselect.com/198203/article
Perspective (E-pub Abstract Ahead of Print) Author(s): Alessandro Gozzetti*, Monica Bocchia Journal Name: Reviews on Recent Clinical Trials Abstract: Minimal residual disease (MRD) detection represents a great advancement in multiple...
Conclusion/Relevance: MRD has proven as the best prognosticator in many trials and promises to enter also in clinical practice to guide future therapy.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34826411/
1 Massachusetts General Hospital Cancer Center, Boston, MA, USA. 2 Memorial-Sloan Kettering Cancer Center, New York, NY, USA. 3 Beigene, San Mateo, CA, USA. 4 Genentech, San Francisco, CA, USA....
Conclusion/Relevance: BOVen was well tolerated and met its primary endpoint, with 33 (89%) of 37 previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma reaching undetectable MRD in both peripheral blood and bone marrow despite a median treatment duration of only 10 months, owing to our undetectable...
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34754015/
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August...
Conclusions: The addition of daratumumab has shown high clinical efficacy and acceptable toxicity profile for the treatment of NDMM and RRMM regarding the endpoints examined.
A Cost Impact Analysis of clonoSEQ ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34480748/
doi: 10.1007/s40487-021-00169-x. 1 MArS Market Access & Pricing Strategy GmbH, Geffelbachstraße 6, 79576, Weil am Rhein, Germany. 2 State University Baden-Wuerttemberg, Lörrach, Germany. 3 University of Applied Sciences Ravensburg-Weingarten, Württemberg,...
Conclusions: Based on the underlying model, clonoSEQ® can support German health insurance funds to use high-cost drugs more efficiently in the treatment of myeloma.